Introduction
Lifelong immunosuppressive drug therapy is currently essential for allograft survival, but at the same time the drugs used are immunologically non-specific and therefore potentially harmful. Since the pioneering experiments of Billingham and colleagues, 1 the establishment of donor-specific tolerance in transplant recipients has been a primary goal. Following induction of this immunological state, recipients are unable to make a destructive immune response to donor alloantigen yet remain fully competent in their response to all other immune challenges. Inducing stable tolerance would reduce or abolish the requirement for global immunosuppression following allogeneic organ transplantation, thereby eliminating the harmful side-effects associated with this type of therapy such as cancers, heart disease and renal damage. 2 Not only is this the ideal immunological solution, but indirectly this would increase the number of organs available for transplantation as fewer recipients would lose their transplants thereby alleviating the current acute shortage.
Importantly, we have demonstrated previously that exposure of the recipient to the whole range of donor MHC class I and class II alloantigens is not necessary to induce immunological unresponsiveness to a fully allogeneic cardiac graft. 3 The administration of autologous tissue, modified to express a single alloantigen as a transgene, has been shown to be a successful strategy for inducing operational tolerance in vivo. 3, 4 The potential of syngeneic bone marrow cells (BMCs) bearing alloantigen to induce tolerance in animal models has previously been demonstrated in this and other laboratories using transgenic or gene therapy strategies. [4] [5] [6] [7] [8] Most gene therapy protocols involving BMCs have employed replication-defective recombinant Moloney murine leukaemia virus (MMLV)-based retroviruses due in part to their ability to stably integrate the transferred genes into the genome of the host cell. The ability of replication-defective, E1-deleted, recombinant adenovirus vectors to transduce whole bone marrow is less well characterised, but these vectors have been shown to be highly effective at transducing many cell types at different developmental stages. 9 To explore the ability of recombinant adenovirus to induce immunological unresponsiveness, we have constructed an E1-deleted replication-defective recombinant adenovirus encoding the donor-specific MHC class I gene, H-2K b under the control of the constitutive Simian virus 40 (SV40) promoter, AdSV40K b . We have used this construct to investigate: (1) whether recombinant adenovirus was a suitable vector for the transduction of BMCs; and (2) whether delivery of adenovirus encoding a single donor alloantigen to recipient BMCs could induce experimental immunological unresponsiveness (as defined by long-term allograft survival) to a fully allogeneic cardiac graft. Figure  1c) . No amplicons were detected in the untransduced BM DNA samples (Figure 1c) . Furthermore, a similar correlation in the increase of amplicon intensity was observed when a K b -specific PCR was carried out on the same samples (data not shown).
Results

Transduction
Pretreatment with syngeneic BMCs transduced with AdSV40K
b in combination with depleting anti-CD4 mAb prolonged allograft survival Administration of a depleting anti-CD4 mAb in combination with donor BMCs has been shown to allow a 10-fold reduction in the number of cells required to achieve long-term graft survival. 4 As the transduction efficiency of BMCs with AdSV40K b was shown to be 9% ( Figure  1b) , we elected to combine treatment with AdSV40K btransduced BM with anti-CD4 therapy to facilitate the induction of specific immunological unresponsiveness.
A control adenovirus encoding the reporter gene, ␤-gal, was used in order to eliminate any non-specific effects arising from delivering syngeneic BMCs or ex vivo adenovirus transduction of BMCs. When recipient CBA mice were injected intravenously on day Ϫ27 with 5 × 10 6 recipient CBA BMCs that had been transduced ex vivo for 4 h with AdRSV␤gal at an MOI of 20 in combination with 2 × 50 g doses of YTA3.1 administered on days Ϫ28 and Ϫ27 pre-transplantation, the survival of fully-MHC mismatched C57BL/10 cardiac allografts was not prolonged compared with anti-CD4 treatment alone (MST = 10 days; n = 5; Figure 2 ). In contrast, intravenous administration of 5 × 10 6 CBA BMCs transduced ex vivo b at an MOI of 20 to CBA/Ca mice on day -27, in combination with 2 × 50 g of depleting anti-CD4 mAb (YTA3.1) on days Ϫ28 and Ϫ27 pre-transplantation resulted in demonstrated significant prolongation of fully allogeneic C57BL/10 cardiac grafts (MST >100 days; n = 5; Figure 2 ; P Ͻ 0.05).
Recipient CBA/Ca mice (H-2 k ) treated intravenously with 50 g of a depleting anti-CD4 mAb (YTA3.1) on day Ϫ28 and day Ϫ27 with respect to cardiac transplantation on day 0 promptly rejected fully MHC-mismatched C57BL/10 (H-2 b ) cardiac grafts (MST = 9 days; n = 4; Figure 2 ). When 5 × 10 6 transgenic CBK (H-2 k + K b ) BMCs were delivered intravenously to the recipient mice on day Ϫ27 in addition to the YTA3.1 treatment, all C57BL/10 allografts exhibited long-term survival (MST >100 days; P Ͻ 0.01; n = 5; Figure 2 ).
We were interested to determine whether the duration of ex vivo transduction of BMCs influenced their ability to induce prolonged graft survival. We hypothesised that there would be a balance between the period of time required to achieve efficient gene transfer without damaging the BMCs. Previous experiments in our laboratory using a replication-defective recombinant retrovirus to deliver the K b gene to recipient BMCs showed that long periods of transduction in ex vivo culture were to the detriment of the induction of unresponsiveness (W Wong, unpublished observation). In order to assess the effect of a prolonged period of ex vivo transduction, recipient BMCs were transduced with AdSV40K b for up to 24 h. All other parameters including the MOI remained constant. The number of recipients with long-term surviving C57BL/10 cardiac allografts was lower after transduction for 24 h when compared with the survival obtained after 4 h transduction (40% long-term survival; MST = 71 days; n = 5; Figure 2 ; NS). These data suggest that increasing the time of transduction may have an adverse effect on the ability of transduced cells to induce unresponsiveness.
In vivo tracking of CBK and AdSV40K b -transduced BMCs delivered to CBA mice in combination with depleting anti-CD4 mAb
In order to determine whether graft survival correlated with alloantigen persistence, we set up a series of experiments to monitor K b expression levels following alloantigen delivery. Following intravenous delivery of 5 × 10 6 CBK BMCs into CBA mice in combination with two doses of YTA3.1, spleen, mesenteric lymph nodes and thymi were harvested at day 3, 7, 14 and 28 after injection. As a control, tissues from mice receiving YTA3.1 alone were also collected on day 3. cDNA was synthesised from mRNA extracted from these tissues and K b cDNA was detected by PCR analysis. Within the spleen, a positive signal for K b mRNA was detected at days 3 and 7 following infusion of 5 × 10 6 CBK BMCs with a detection level of 1:1000 mRNA molecules (Figure 3a, c) . K b mRNA was also detected at day 14 (in one mouse only) and at day 28 (both mice) post-infusion, albeit at the lower level of detection between 1:10 000 and 1:100 000. No K b mRNA was detectable in the spleens of the negative control mice treated with YTA3.1 alone. The success of all reverse transcription reactions was confirmed by determination of a positive HPRT signal. In the mesenteric lymph nodes, K b signal was detected at day 3 (between 1:1000 and 1:10 000), day 7 (one mouse between 1:1000 and 1:10 000, the other 1:1000), day 14 (between 1:1000 and 1:10 000), and in one mouse only at day 28 (1:10 000) (Figure 3a, c) . In the thymus, K b signal was detected in one mouse at day 3 (1:10 000), one mouse at day 7 (1:10 000 > 1:100 000) and one mouse at day 28 (Ͻ1:100 000) (Figure 3a, c) .
We then wanted to determine whether K b mRNA could be detected following administration of the same dose of recipient BMCs (5 × 10 
No evidence for the presence of anti-adenovirus antibodies following the delivery of AdSV40K btransduced recipient BMCs
One of the major drawbacks in using recombinant adenovirus for gene transfer applications is the generation of a potent immune response directed against adenovirus coat proteins which can limit transgene expression and prevent effective re-administration of the vector. 10 We sampled sera from CBA recipient mice that had received a day Ϫ27 pretreatment of ex vivo AdSV40K b -transduced CBA BMCs in combination with YTA3.1 in order to determine whether adenovirus-specific antibodies were produced in response to the vector. As a positive control, naive mice were primed subcutaneously on day 0 with 2.5 × 10 7 p.f.u. of AdSV40K b , boosted with the same dose of virus on day 18, and serum was harvested on day 28. Compared with the standard primed serum sample, none of the sera from mice receiving CBA BM transduced with AdSV40K b for 4 or 24 h and subsequently transplanted with H-2 b cardiac allografts had any detectable antiadenovirus antibodies (n = 9; data not shown). These serum samples were harvested either after the graft had rejected (day 45) or at the time of death in the case of mice with long-term surviving allografts (day 99-100). As a control, transplanted mice receiving YTA3.1 alone also showed no detectable anti-adenovirus antibody production (n = 2).
It is possible that any early anti-adenovirus antibody responses would have been missed in these samples, especially as some were taken 127 days after the AdSV40K b -transduced BM had been administered. We therefore carried out a time-course analysis to detect potential anti-Ad antibody responses in mice pretreated with two doses of YTA3.1 on day Ϫ1 and day 0 and 5 × 10 6 CBA BMCs transduced with AdSV40K b at a MOI of 20 for 4 h on day 0. As a negative control, mice received YTA3.1 alone. Two mice were used at each time-point. No anti-adenovirus antibody was detected in any of the pretreated mice (day 3, 7, 14 and 28 after BM infusion) or the negative controls.
Discussion
Previous work in this laboratory has demonstrated that exposure to only one donor MHC molecule is sufficient to induce specific immunological unresponsiveness and in some circumstances operational tolerance to fully allogeneic grafts expressing several other major and minor histocompatibility antigens, providing that the allografts express the MHC molecule to which the recipient has been tolerised. 3, 4, 11 One of our goals is to translate these observations to induce specific immunological unresponsiveness in clinical transplantation by pretreating transplant recipients with syngeneic BMCs transduced to express a donor MHC gene(s). In order to achieve this we need to evaluate the potency of different vectors to deliver donor genes to BM and induce unresponsiveness Gene Therapy in well-characterised experimental models. This study demonstrates that transfer of a single donor MHC class I gene (H-2K b ) to recipient bone marrow using an E1-deleted recombinant adenovirus can result in the longterm survival of fully allogeneic cardiac grafts (Figure 2) .
Although retrovirus-based gene therapy vectors are relatively efficient at transducing bone marrow cells, 12 they require active cellular turnover for efficient incorporation of the genome. This requirement means that target cell populations must either be actively dividing, or need to be pretreated with compounds such as 5-flurouracil in order to promote cell cycling. 13 One major advantage of adenoviral over retroviral vectors for gene transfer is their ability to transduce a wide range of cell types with a high efficiency (now shown to be dependent upon the widespread presence of the Coxsackie adenovirus receptor 14 ), whether the cells are actively dividing or quiescent. 9 Having first demonstrated that recipient strain BMCs could be transduced with AdSV40K The level of transgene expression has been shown to be critically dependent upon the ratio of viral particles to target cells. However, it must be remembered that at significantly higher concentrations of adenovirus vector (MOI >500), toxic effects such as the inhibition of BM progenitor colonies have been demonstrated. 15 As a result of these observations and concerns over inducing a neutralising anti-adenovirus antibody response, we transduced recipient bone marrow cells at the relatively low MOI of 20. In this system, we have shown that the characteristic ability of adenovirus to generate an immune response played no role in this experimental model following the administration of ex vivo transduced BM. No anti-adenovirus antibodies were detected at any timepoint (day 3 to day 126 after injection) in sera from mice pretreated with adenovirus-transduced BM in combination with anti-CD4 mAb. This result was expected since transduced BM had been washed thoroughly in PBS before injection and so no viral particles that could potentially have resulted in the mouse being primed to adenovirus were directly transferred into recipient mice. Moreover, all the mice were treated with a depleting anti-CD4 mAb at the time of infusion of the BMCs that would have significantly reduced the amount of T cell help available.
The role of donor cell microchimerism in allograft survival is controversial. Data from Ko et al 16 using a cyclosporin-induced tolerance model in the rat, demonstrate the clear advantage of the presence of allogeneic cells in the early induction phase of tolerance induction. Depletion of donor passenger leukocytes 18 days after transplantation showed no detectable adverse effects on graft function and infiltration. Conversely, donor cell depletion on the day of transplantation resulted in severe chronic rejection and long-term graft. Microchimerism was consistently detected in the day 18 mAb-treated mice up to 2 weeks after transplantation, but was only found in one rat receiving the day 0 mAb treatment. In addition, Bushell et al 17 have also demonstrated that the presence of alloantigen during the induction phase is vital to induce tolerance, but that microchimerism was not. Having established in our model the ability of both CBK BMCs and CBA BMCs transduced with AdSV40K b to prolong graft survival, we wanted to determine the persistence and fate of H-2K b+ cells following injection in the tolerance induction phase leading up to the time of transplantation. When a low dose of 5 × 10 4 CBK BMCs was delivered in combination with two doses of YTA3.1, K b mRNA was only detected in the mesenteric lymph nodes 3 days after injection (data not shown) despite 83% of recipients in an equivalent group accepting K b+ grafts for greater than 100 days (personal communication, JS Billing). These data suggest that unresponsiveness can be achieved in the absence of microchimerism detectable using this PCR assay. Sonntag et al 8 have also reported similar findings following retroviral transfer of MHC class II genes to recipient BM in a renal allograft model in miniature swine. Increasing the dose to 5 × 10 6 CBK BMCs in combination with YTA3.1 pretreatment, enabled us to detect K b mRNA at all time-points up until the time of transplantation in the periphery but less frequently in the thymus (Figure 3a) . Overall, the frequency and level of alloantigen mRNA detection following CBK BMC infusion was significantly higher compared with the same dose of AdSV40K b -transduced CBA BM pretreated mice, where no K b expression could be detected in the recipient mice after infusion (Figure 3b) , correlating to the levels of surface K b protein measured by flow cytometry described earlier.
RT-PCR was also carried out on the spleens of five recipients with long-term grafts 99 days after transplantation (two 5 × 10 6 AdSV40K b -transduced CBA BM and three 5 × 10 6 CBK BM pretreated mice). The fact that no K b mRNA was detected in the examined tissues of any of the mice (data not shown) correlates with the hypothesis that detectable microchimerism is not a prerequisite for graft survival following alloantigen pre-treatment. 18, 19 Immunoregulatory T cells (Treg) have been shown to be responsible for the induction and maintenance of operational tolerance to an allograft after exposure to donor alloantigen in combination with anti-CD4 therapy. [20] [21] [22] We hypothesise that a population of H-2K 23 All mice were cared for and used in strict accordance with the Animals (Scientific Procedures) Act, 1986. Mice were sex-and age-matched between 8-12 weeks of age at the time of first experimental procedure.
Vector construction and virus production
The strategy we employed to produce recombinant adenovirus has been widely used by other laboratories and was originally described by McGrory et al. 24 An adenovirus transfer plasmid vector lacking all promoter sequences was constructed following removal of the RSV promoter/enhancer region from pXCXRSV . pJM17, a plasmid that contains the entire adenovirus 5 genome with a disruptive insertion in the E1 region 24 was co-transfected with pXCXSV40K b by calcium phosphate precipitation into the human embryonic kidney epithelial complementary cell line, 293 resulting in the production of infectious recombinant viral particles. All cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Sigma, Poole, UK) supplemented with 10% foetal calf serum (FCS; Life Technologies, Paisley, UK), 4 mm l-glutamine, penicillin (45 g/ml), kanamycin (90 g/ml), streptomycin (45 g/ml). Cells were incubated at 37°C in 5% CO 2 . Viral clones were isolated by plaque purification (cells overlaid with an equal mixture of 2% SeaPlaque low-melting point agarose (FMC Bioproducts, ME, USA) and 2× modified Eagle's medium (MEM; Life Technologies) and then analysed by transduction of a target fibroblast cell line, NIH3T3, with viral supernatant followed by flow cytometric analysis of the cells using a biotinylated mouse anti-H-2K b antibody (Pharmingen, San Diego, CA, USA). Adenovirus was purified on a saturated caesium chloride gradient, titred and stored as described previously. 25 Viral DNA isolation Cells were lysed by resuspending the pellet in 0.6% SDS, 10 mm EDTA, 200 g/ml Proteinase K (Sigma, Poole, UK), made up to 400 l with TE buffer. The pellet was incubated for 2 h at 37°C, then 100 l of 5 m NaCl was added to precipitate the cellular DNA. After leaving at 4°C overnight, the tubes were centrifuged at 13 000 r.p.m., for 30 min at 4°C. The supernatant was retrieved and a phenol/chloroform extraction was carried out to remove any viral DNA present in the samples. Viral DNA was precipitated with two volumes of ice cold 100% ethanol. The DNA was pelleted, dried and resuspended in 40 l of TE buffer.
Bone marrow transduction BM was harvested from 24-36-week-old CBA/Ca mice as described previously. 4 BMCs were resuspended to 5-10 × 10 6 /ml in DMEM plus supplements and transduced at 37°C for 4 h with AdSV40K b at a multiplicity of infection (MOI) of 20. BMCs were then washed in phosphatebuffered saline (PBS) and resuspended to 10 × 10 6 /ml in sterile saline before intravenous injection via the penile vein of recipient mice. 6 ) cells were prepared for flow cytometric analysis and resuspended in FACS buffer (PBS, 2% FCS, 1 m sodium azide). Relevant cells were stained with biotinylated anti-H-2K b (AF6-88.5). Streptavidin-conjugated PE was used as a second-stage reagent for biotinylated primary antibody. All antibodies were purchased from Pharmingen (San Diego, CA, USA). A FACSort (Becton Dickinson, Oxford, UK) was used for acquisition and data was analysed using CellQuest software (Becton Dickinson).
Flow cytometry
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Anti-CD4 pretreatment
The YTA3.1.2 hybridoma producing an IgG2b rat antimouse depleting CD4 monoclonal antibody (YTA3.1) 27 was a kind gift from Professor Herman Waldmann (Sir William Dunn School of Pathology, University of Oxford). The antibody was grown as ascites in (LOU × DA) F1 rats and purified by ammonium sulphate precipitation followed by DEAE Sephacel ion exchange chromatography. Purity was confirmed by SDS-PAGE and scanning laser densitometry. 50 g of purified monoclonal antibody in 0.5 ml of saline was administered intravenously per injection.
Reverse-transcriptase polymerase chain reaction
Total RNA was extracted from snap frozen tissue using homogenisation in 1 ml of RNAzol B solution (Biogenesis, Poole, UK). For each sample, 5 g oligo-dT (Promega, Southampton, UK) was annealed to 10 g of isolated RNA in the presence of 30 U of RNAsin (Promega) by heating the samples to 60°C for 5 min then cooling on ice for 3 min. Reverse transcription was carried out in 1 × first strand buffer, 10 mm dithiothreitol, 10 U MMLV reverse transcriptase (Life Technologies) and 1 mm dNTPs (Promega) for 90 min at 37°C and 10 min at 70°C. PCR reactions were carried under the following conditions: 1 × NH 4 buffer, 1.5 mm MgCl 2 , 2 mm dNTPs, 20 pmols/primer (MWG Biotech, Milton Keynes, UK), 1 U Taq polymerase. H-2K b -specific primers were: 5Ј CAC-TATTCAGGTGATCTCT 3Ј (sense), 5Ј AGAGAAT-GAGGGTCATGAAC 3Ј (antisense). HPRT-specific primers were: 5Ј GTTGGATACAGGCCAGACTTTGTT 3Ј (sense), 5Ј GAGGGTAGGCTGGCCTATAGGCT 3Ј (antisense); E2A-specific primers were: 5Ј CGTG TCGTCCCCGTCCCCGTC 3Ј (sense), 5Ј CACAGCG GTGCAGCCACAACG 3Ј (antisense). Annealing temperature for the H-2K b primer set was 50°C; HPRT primer set, 60°C; E2A primer set, 60°C.
Anti-adenovirus antibody assay
In order to obtain a positive standard, two CBA mice were primed with adenovirus by injecting 2.5 × 10 7 p.f.u. of recombinant adenovirus in 500 l of saline subcutaneously. Antigen rechallenge by repeat administration of virus at the same dose was carried out 18 days after the primary injection. Serum was then harvested at day 28 after initial injection for anti-adenovirus antibody analyGene Therapy sis. Relative antibody titre was determined by enzymelinked immunosorbent assay (ELISA) as previously described. 28 Briefly, tripling dilutions of serum starting at 1:10 and ending at 1:21 870 were added to wells of a 96-well plate (duplicate wells with coating of AdSV40K b , one well without coating). Following washing of the wells, the presence of anti-adenovirus antibody was detected by incubation with anti-mouse IgG Fc specific peroxidase conjugate (Sigma). Following development of the coloured substrate, the optical density was measured at 490 nm. Final measured OD was the OD of the negative control well subtracted from the mean ODs of the two wells at the same serum dilution that were coated with adenovirus. A standard curve (four-parameter curve fit) of the serial dilutions from the primed mice was drawn using the SoftMax software package. In order to compare samples qualitatively, titres were calculated as 100 × (concentration of sample serum at 1/2 maximum OD)/(concentration of standard primed serum at 1/2 maximum OD).
